Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
February 15 2024 - 7:00AM
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced the appointment of Steve
Meyers as Chief Commercial Officer.
“As we continue our commitment to advancing our drug portfolio
in order to enhance the quality of life for patients, I am thrilled
to announce the promotion of Steve Meyers to the role of Chief
Commercial Officer,” said Antony Mattessich, CEO of Ocular
Therapeutix. “Steve has consistently demonstrated exceptional
leadership, strategic vision and a deep understanding of our
mission. With his expertise and dedication, I am confident he will
play a pivotal role in driving Ocular’s commercial efforts
forward.”
“I am truly honored by this opportunity to serve as Chief
Commercial Officer," said Steve Meyers. “Over the past two years,
I’ve been inspired by our commitment to develop transformational
treatments to enhance people’s vision and quality of life. I’m
eager to continue driving innovation and ultimately making a
meaningful difference for patients and shareholders alike.”
Mr. Meyers has over 20 years of commercial experience, including
several buy and bill, specialty pharmacy and innovative technology
product launches in highly competitive markets. Mr. Meyers served
in other commercial capacities at leading biotechnology
organizations including Regeneron, AbbVie, and Procter &
Gamble. Prior to joining Ocular, Mr. Meyers served as Vice
President of Sales at Flexion Therapeutics in the orthopedic space.
Mr. Meyers holds a B.S. from Louisiana State University in
Cardiopulmonary Science.
About Ocular Therapeutix, Inc.Ocular
Therapeutix, Inc. is a biopharmaceutical company focused on
the formulation, development and commercialization of innovative
therapies for diseases and conditions of the eye using its
proprietary bioresorbable hydrogel-based formulation technology
ELUTYX™. Ocular Therapeutix’s first commercial drug product,
DEXTENZA®, is an FDA-approved corticosteroid for the treatment of
ocular inflammation and pain following ophthalmic surgery and
ocular itching associated with allergic conjunctivitis. Ocular
Therapeutix’s earlier stage development assets include: AXPAXLI
(axitinib intravitreal implant), currently in a pivotal Phase 3
trial for the treatment of wet AMD and a Phase 1 clinical trial for
the treatment of diabetic retinopathy; PAXTRAVA™ (travoprost
intracameral implant, also known as OTX-TIC), currently in a Phase
2 clinical trial for the treatment of primary open-angle glaucoma
or ocular hypertension; and OTX-CSI (cyclosporine intracanalicular
insert) for the chronic treatment of dry eye disease and OTX-DED
(dexamethasone intracanalicular insert) for the short-term
treatment of the signs and symptoms of dry eye disease, both of
which have completed Phase 2 clinical trials.
Forward Looking StatementsAny statements in
this press release about future expectations, plans, and prospects
for the Company and other statements containing the words
"anticipate," "believe," "estimate," "expect," "intend", "goal,"
"may", "might," "plan," "predict," "project," "target,"
"potential," "will," "would," "could," "should," "continue," and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors. Such forward-looking statements involve substantial risks
and uncertainties that could cause the Company’s preclinical and
clinical development programs, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the timing and costs involved
in commercializing DEXTENZA or any product or product candidate
that receives regulatory approval; the ability to retain regulatory
approval of DEXTENZA or any product or product candidate that
receives regulatory approval; the ability to maintain and the
sufficiency of product, procedure and any other reimbursement codes
for DEXTENZA; the initiation, design, timing, conduct and outcomes
of clinical trials, including the Phase 3 SOL-1 trial evaluating
AXPAXLI for the treatment of wet AMD; the risk that the FDA will
not agree with the Company’s interpretation of the written
agreement under the SPA; the risk that even though the FDA has
agreed with the overall design of the SOL-1 trial, the FDA may not
agree that the data generated by the SOL-1 trial supports potential
marketing approval; uncertainty as to whether the data from earlier
clinical trials will be predictive of the data of later clinical
trials, particularly later clinical trials that have a different
design or utilize a different formulation than the earlier trials;
availability of data from clinical trials and expectations for
regulatory submissions and approvals; the Company’s scientific
approach and general development progress; uncertainties inherent
in estimating the Company’s cash runway, future expenses and other
financial results, including its ability to fund future operations,
including clinical trials; Company’s existing indebtedness and the
ability of the Company’s creditors to accelerate the maturity of
such indebtedness upon the occurrence of certain events of default;
the Company’s ability to enter into strategic alliances or generate
additional funding on a timely basis, on favorable terms, or at
all; and other factors discussed in the “Risk Factors” section
contained in the Company’s quarterly and annual reports on file
with the Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
the Company’s views as of the date of this press release. The
Company anticipates that subsequent events and developments will
cause the Company’s views to change. However, while the Company may
elect to update these forward-looking statements at some point in
the future, the Company specifically disclaims any obligation to do
so, whether as a result of new information, future events or
otherwise, except as required by law. These forward-looking
statements should not be relied upon as representing the Company’s
views as of any date subsequent to the date of this press
release.
InvestorsOcular
TherapeutixDonald NotmanChief Financial
Officerdnotman@ocutx.com
or
ICR WestwickeChris Brinzey, 339-970-2843Managing
Directorchris.brinzey@westwicke.com
MediaICR WestwickeBen Shannon,
443-213-0495ben.shannon@westwicke.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Apr 2024 to May 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From May 2023 to May 2024